Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma

Zhang, Bin; Wang, Zhijun; Wu, Liangliang; Zhang, Meng; Li, Wei; Ding, Jianhua; Zhu, Jun; Wei, Huafeng; Zhao, Ke
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous family of myeloid cells that suppress T cell immunity in tumor-bearing hosts. In patients with colon cancer, MDSCs have recently been described as Lin−/lowHLA-DR−CD11b+CD33+ cells correlating with cancer stage, metastasis and chemotherapy response. To learn in more detail the dynamic change and clinical relevance of circulating and tumor-infiltrating Lin−/lowHLA-DR−CD11b+CD33+ MDSC in colorectal cancer, we harvested the blood from 64 patients with varying stage of colorectal cancer and tumor and matched paraneoplastic tissues from 5 patients with advanced colorectal cancer, subjected them to multicolor flow cytometric analysis of percentage, absolute number and phenotype of MDSC and finally characterized their immunosuppressive functions. Our results demonstrate that peripheral blood from colorectal cancer patients contains markedly increased percentage and absolute number of Lin−/lowHLA-DR−CD11b+CD33+ MDSCs compared with healthy individuals, and this increase is closely correlated with clinical cancer stage and tumor metastasis but not primary tumor size and serum concentrations of cancer biomarker. A similar increase of MDSCs was also observed in the tumor tissues. Phenotyping MDSCs shows that they express high CD13 and CD39, low CD115, CD117, CD124 and PD-L1, and devoid of CD14, CD15 and CD66b, reminiscent of precursor myeloid cells. MDSCs from cancer patients but not healthy donors have the immunosuppressive activity and were able to inhibit in vitro autologous T-cell proliferation. Collectively, this study substantiates the presence of increased immunosuppressive circulating and tumor-resident Lin−/lowHLA-DR−CD11b+CD33+ MDSCs in patients with colorectal cancers correlating with cancer stage and metastasis, and suggests that pharmacologic blockade of MDSCs should be considered in future clinical trials.


Related Articles

  • MicroRNA in colorectal cancer: from benchtop to bedside. Wu, William K.K.; Law, Priscilla T.Y.; Lee, Chung W.; Cho, Chi H.; Fan, Daiming; Wu, Kaichun; Yu, Jun; Sung, Joseph J.Y. // Carcinogenesis;Mar2011, Vol. 32 Issue 3, p247 

    Colon carcinogenesis represents a stepwise progression from benign polyps to invasive adenocarcinomas and distant metastasis. It is believed that these pathologic changes are contributed by aberrant activation or inactivation of protein-coding proto-oncogenes and tumor suppressor genes. However,...

  • Pathobiology of cancer metastasis: a short account.  // Cancer Cell International;2012, Vol. 12 Issue 1, p24 

    The article looks at the pathobiology of cancer metastasis. It explores how cancer cells express signal transduction pathways which are significant for normal stem cell function, with a cancer cell phenotype in cancerization and metastasis. The analogies between some of the genetic programs of...

  • Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Hsu, Hung-Chih; Liu, Yi-Shiuan; Tseng, Kai-Chi; Hsu, Cheng-Lung; Liang, Ying; Yang, Tsai-Sheng; Chen, Jinn-Shiun; Tang, Rei-Ping; Chen, Shu-Jen; Chen, Hua-Chien // International Journal of Colorectal Disease;Nov2013, Vol. 28 Issue 11, p1535 

    Background: The leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) is an adult intestinal stem cell marker frequently detected in human colorectal cancers (CRCs). However, the value of Lgr5 level in CRC prognosis and treatment prediction has not been well characterized. Methods:...

  • Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Ni, Jie; Cozzi, Paul; Duan, Wei; Shigdar, Sarah; Graham, Peter; John, Kearsley; Li, Yong // Cancer & Metastasis Reviews;Dec2012, Vol. 31 Issue 3/4, p779 

    Despite significant advances in surgery, radiotherapy and chemotherapy to treat prostate cancer (CaP), many patients die of secondary disease (metastases). Current therapeutic approaches are limited, and there is no cure for metastatic castration-resistant prostate cancer (CRPC). Epithelial cell...

  • Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Takahashi, Masanobu; Sung, Bokyung; Shen, Yan; Hur, Keun; Link, Alexander; Boland, C. Richard; Aggarwal, Bharat B.; Goel, Ajay // Carcinogenesis;Dec2012, Vol. 33 Issue 12, p2441 

    Colorectal cancer (CRC) is a complex disease with genetic and epigenetic alterations in many key oncogenes and tumor suppressor genes. The active principle of a gum resin from Boswellia serrata, 3-acetyl-11-keto-β-boswellic acid (AKBA), has recently gained attention as a chemopreventive...

  • ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. Vishnubhotla, Ramana; Shan Sun; Huq, Jameela; Bulic, Marinka; Ramesh, Anil; Guzman, Grace; Cho, Michael; Glover, Sarah C. // Laboratory Investigation (00236837);Nov2007, Vol. 87 Issue 11, p1149 

    The ROCK-II isoform of Rho's downstream effector, Rho kinase, has been linked with greater invasion and metastasis in solid tumors. We have previously shown that ROCK-II is overexpressed at the advancing edge of colon cancers. The mechanism whereby ROCK-II contributes invasion, particularly in...

  • Colorectal Cancer Migration and Invasion Initiated by microRNA-106a. Bo Feng; Tao Tao Dong; Lin Lin Wang; Hou Min Zhou; Hong Chao Zhao; Feng Dong; Kyprianou, Natasha; Min Hua Zheng // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    MicroRNAs have been implicated in the regulation of several cellular signaling pathways of colorectal cancer (CRC) cells. Although emerging evidence proves that microRNA (miR)-106a is expressed highly in primary tumor and stool samples of CRC patients; whether or not miR-106a mediates cancer...

  • Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26. Cutler, Murray J.; Lowthers, Erica L.; Richard, Cynthia L.; Hajducek, Dagmar M.; Spagnuolo, Paul A.; Blay, Jonathan // BMC Cancer;11/10/2015, Vol. 15, p1 

    Background: Recurrence of colorectal cancer (CRC) may arise due to the persistence of drug-resistant and cancer-initiating cells that survive exposure to chemotherapy. Proteins responsible for this recurrence include the chemokine receptor CXCR4, which is known to enable CRC...

  • MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Tang, Jie-Ting; Wang, Ji-Lin; Du, Wan; Hong, Jie; Zhao, Shu-Liang; Wang, Ying-Chao; Xiong, Hua; Chen, Hui-Min; Fang, Jing-Yuan // Carcinogenesis;Aug2011, Vol. 32 Issue 8, p1207 

    Aberrant methylation has been shown to trigger the inactivation of tumor suppressor genes during tumorigenesis. MicroRNAs (miRNAs) have been found deregulated in human colorectal cancer (CRC), and some of them may function as tumor suppressor genes. Here, we investigated CpG island promoter...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics